David H Kirn
Jennerex Biotherapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David H Kirn as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01171651 · A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular CarcinomaJennerex Biotherapeutics · completed · Carcinoma, Hepatocellular · study director
- Ph1/Ph2NCT00429312 · A Study of Recombinant Vaccinia Virus to Treat Malignant MelanomaJennerex Biotherapeutics · completed · Melanoma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:51 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- 895 citationsRCR 17.8
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.Nat Med · 2013660 citationsRCR 17.7
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Nature · 2011466 citationsRCR 10.9
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.Lancet Oncol · 2008428 citationsRCR 8.7
- A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.Clin Cancer Res · 2003402 citationsRCR 8.3
- 220 citationsRCR 5.6
- 195 citationsRCR 4.0
- Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.Mol Ther · 2015136 citationsRCR 4.2
- First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.Mol Ther · 2015131 citationsRCR 4.0
- 130 citationsRCR 3.2